6:10 am Prana Biotech meets primary endpoint in Phase 2 REACH2HD clinical study of PBT2 for treating Huntington disease; preliminary evidence suggests PBT2 250mg reduced atrophy of brain tissue in areas affected in Huntington disease, seen
View todays social media effects on PRAN
View the latest stocks trending across Twitter. Click to view dashboard
See who Prana is hiring next, click here to view
